A
ABIONYX
Developing of novel therapies for the treatment of cardiovascular and metabolic diseases
About ABIONYX
ABIONYX Pharma is a cutting-edge biotech company focused on discovering and developing innovative therapies for patients who currently lack effective treatment options. The company operates in the biotechnology sector, specifically targeting cardiovascular diseases and associated metabolic disorders such as Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH). ABIONYX also explores HDL-targeted drug delivery platforms in the field of oncology, particularly immuno-oncology. The business model involves leveraging existing development assets inherited from CERENIS Therapeutics and forming strategic partnerships to advance its research and development activities. ABIONYX generates revenue through the development and commercialization of its proprietary therapies and drug delivery platforms.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2005
- Headquarters
- Balma, France
- Listing
- IPO 2015
- Employees
- 8
- Open positions
- None listed
- Dealroom signal
- 28.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Telecommunications, Personal Health, Diabetes, Risk Management, Biotechnology, Drug Development, Cardiology and cardiovascular, Metabolism
- Business model
- Manufacturing, SaaS
- Client focus
- b2b
- Investment activity
- 1 company, latest Nov 2017
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO EQUITYOther financing | Jun 2026 | $36M | — | Fenja Capital | ↗ |
| POST IPO EQUITYOther financing | Dec 2025 | $2M | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
| Year | Revenue | Growth | EBITDA | Margin |
|---|---|---|---|---|
| 2026 | $5.1M | +14.7% | −$21M | -408.2% |
| 2025 | $4.5M | -10.7% | −$5.7M | -127.7% |
| 2024 | $5M | -1.9% | −$4.5M | -89.4% |
| 2023 | $5.1M | -11.7% | −$3.4M | -66.8% |
| 2022 | $5.8M | +678.1% | −$4.4M | -76.4% |
| 2021 | $743K | — | −$6.3M | -843.7% |
| 2020 | $0 | — | −$2.1M | — |
Growth signals
Latest recorded traffic for ABIONYX is 3.7K monthly website visits, up 117.6% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A6 investors entered at this stage
HealthCap
Sofinnova Partners
Alta Partners- EVEDF Ventures
OrbiMed
TVM Capital Life Science
Series B and later2 investors entered at this stage
Fonds Stratégique d'Investissement
Fenja Capital
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about ABIONYX on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ABIONYX’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.